• Je něco špatně v tomto záznamu ?

Identification of potential molecular targets for the treatment of cluster 1 human pheochromocytoma and paraganglioma via comprehensive proteomic characterization

O. Vit, P. Talacko, Z. Musil, I. Hartmann, K. Pacak, J. Petrak

. 2023 ; 20 (1) : 39. [pub] 20230925

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23015234

Grantová podpora
AZV NV19-01-00083, NU23-01-00323 Czech Agency for Healthcare Research
UNCE/MED/016 and Cooperatio program, research area BIOLOGY Ministry of Education, Youth, and Sports of the Czech Republic (MSMT CR)
National Institute of Cancer Research - LX22NPO5102 European Union - Next Generation EU, Programme EXCELES

BACKGROUND: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors. New drug targets and proteins that would assist sensitive PPGL imagining could improve therapy and quality of life of patients with PPGL, namely those with recurrent or metastatic disease. Using a combined proteomic strategy, we looked for such clinically relevant targets among integral membrane proteins (IMPs) upregulated on the surface of tumor cells and non-membrane druggable enzymes in PPGL. METHODS: We conducted a detailed proteomic analysis of 22 well-characterized human PPGL samples and normal chromaffin tissue from adrenal medulla. A standard quantitative proteomic analysis of tumor lysate, which provides information largely on non-membrane proteins, was accompanied by specific membrane proteome-aimed methods, namely glycopeptide enrichment using lectin-affinity, glycopeptide capture by hydrazide chemistry, and enrichment of membrane-embedded hydrophobic transmembrane segments. RESULTS: The study identified 67 cell surface integral membrane proteins strongly upregulated in PPGL compared to control chromaffin tissue. We prioritized the proteins based on their already documented direct role in cancer cell growth or progression. Increased expression of the seven most promising drug targets (CD146, CD171, ANO1, CD39, ATP8A1, ACE and SLC7A1) were confirmed using specific antibodies. Our experimental strategy also provided expression data for soluble proteins. Among the druggable non-membrane enzymes upregulated in PPGL, we identified three potential drug targets (SHMT2, ARG2 and autotaxin) and verified their upregulated expression. CONCLUSIONS: Application of a combined proteomic strategy recently presented as "Pitchfork" enabled quantitative analysis of both, membrane and non-membrane proteome, and resulted in identification of 10 potential drug targets in human PPGL. Seven membrane proteins localized on the cell surface and three non-membrane druggable enzymes proteins were identified and verified as significantly upregulated in PPGL. All the proteins have been previously shown to be upregulated in several human cancers, and play direct role in cancer progression. Marked upregulation of these proteins along with their localization and established direct roles in tumor progression make these molecules promising candidates as drug targets or proteins for sensitive PPGL imaging.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015234
003      
CZ-PrNML
005      
20250109141521.0
007      
ta
008      
231010s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12014-023-09428-7 $2 doi
035    __
$a (PubMed)37749499
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vít, Ondřej $u BIOCEV, First Faculty of Medicine, Charles University, Vestec, 25250, Czech Republic $7 xx0327709
245    10
$a Identification of potential molecular targets for the treatment of cluster 1 human pheochromocytoma and paraganglioma via comprehensive proteomic characterization / $c O. Vit, P. Talacko, Z. Musil, I. Hartmann, K. Pacak, J. Petrak
520    9_
$a BACKGROUND: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors. New drug targets and proteins that would assist sensitive PPGL imagining could improve therapy and quality of life of patients with PPGL, namely those with recurrent or metastatic disease. Using a combined proteomic strategy, we looked for such clinically relevant targets among integral membrane proteins (IMPs) upregulated on the surface of tumor cells and non-membrane druggable enzymes in PPGL. METHODS: We conducted a detailed proteomic analysis of 22 well-characterized human PPGL samples and normal chromaffin tissue from adrenal medulla. A standard quantitative proteomic analysis of tumor lysate, which provides information largely on non-membrane proteins, was accompanied by specific membrane proteome-aimed methods, namely glycopeptide enrichment using lectin-affinity, glycopeptide capture by hydrazide chemistry, and enrichment of membrane-embedded hydrophobic transmembrane segments. RESULTS: The study identified 67 cell surface integral membrane proteins strongly upregulated in PPGL compared to control chromaffin tissue. We prioritized the proteins based on their already documented direct role in cancer cell growth or progression. Increased expression of the seven most promising drug targets (CD146, CD171, ANO1, CD39, ATP8A1, ACE and SLC7A1) were confirmed using specific antibodies. Our experimental strategy also provided expression data for soluble proteins. Among the druggable non-membrane enzymes upregulated in PPGL, we identified three potential drug targets (SHMT2, ARG2 and autotaxin) and verified their upregulated expression. CONCLUSIONS: Application of a combined proteomic strategy recently presented as "Pitchfork" enabled quantitative analysis of both, membrane and non-membrane proteome, and resulted in identification of 10 potential drug targets in human PPGL. Seven membrane proteins localized on the cell surface and three non-membrane druggable enzymes proteins were identified and verified as significantly upregulated in PPGL. All the proteins have been previously shown to be upregulated in several human cancers, and play direct role in cancer progression. Marked upregulation of these proteins along with their localization and established direct roles in tumor progression make these molecules promising candidates as drug targets or proteins for sensitive PPGL imaging.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Talacko, Pavel $u Proteomics Core Facility, Faculty of Science, BIOCEV, Charles University, Vestec, 25250, Czech Republic
700    1_
$a Musil, Zdenek $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital, Prague, 12800, Czech Republic
700    1_
$a Hartmann, Igor $u Department of Urology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, 77900, Czech Republic
700    1_
$a Pacak, Karel $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, 20892, USA
700    1_
$a Petrak, Jiri $u BIOCEV, First Faculty of Medicine, Charles University, Vestec, 25250, Czech Republic. jpetr@lf1.cuni.cz
773    0_
$w MED00173375 $t Clinical proteomics $x 1542-6416 $g Roč. 20, č. 1 (2023), s. 39
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37749499 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20250109141515 $b ABA008
999    __
$a ok $b bmc $g 1997058 $s 1201596
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 20 $c 1 $d 39 $e 20230925 $i 1542-6416 $m Clinical proteomics $n Clin Proteomics $x MED00173375
GRA    __
$a AZV NV19-01-00083, NU23-01-00323 $p Czech Agency for Healthcare Research
GRA    __
$a UNCE/MED/016 and Cooperatio program, research area BIOLOGY $p Ministry of Education, Youth, and Sports of the Czech Republic (MSMT CR)
GRA    __
$a National Institute of Cancer Research - LX22NPO5102 $p European Union - Next Generation EU, Programme EXCELES
LZP    __
$a Pubmed-20231010

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace